We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

IV Cocaine Abuse: A Laboratory Model - 3

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00000214
First Posted: September 21, 1999
Last Update Posted: August 31, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
National Institute on Drug Abuse (NIDA)
Columbia University
Information provided by (Responsible Party):
New York State Psychiatric Institute
  Purpose
The purpose of this study is to evaluate the effects of buprenorpine on cocaine taking and on the physiological and subjective effects of cocaine, including cocaine craving in non-opiate dependent cocaine users.

Condition Intervention Phase
Cocaine-Related Disorders Drug: Buprenorphine Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: IV Cocaine Abuse: A Laboratory Model

Resource links provided by NLM:


Further study details as provided by New York State Psychiatric Institute:

Primary Outcome Measures:
  • Direct cocaine effects (caridio, subjective)
  • Interaction of coc/bup on cardio measures
  • Ineraction of coc/bup on coc's subjective effects
  • Effects of buprenorphine on cocaine craving

Estimated Enrollment: 0
Study Start Date: January 1992
Study Completion Date: January 1993
Primary Completion Date: January 1993 (Final data collection date for primary outcome measure)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria
Please contact site for information.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00000214


Locations
United States, New York
Columbia University
New York, New York, United States, 10023
Sponsors and Collaborators
New York State Psychiatric Institute
National Institute on Drug Abuse (NIDA)
Columbia University
Investigators
Principal Investigator: Richard Foltin, Ph.D. Columbia University
  More Information

Publications:
Responsible Party: New York State Psychiatric Institute
ClinicalTrials.gov Identifier: NCT00000214     History of Changes
Other Study ID Numbers: NIDA-06234-3
R01DA006234 ( U.S. NIH Grant/Contract )
R01-06234-3
First Submitted: September 20, 1999
First Posted: September 21, 1999
Last Update Posted: August 31, 2015
Last Verified: December 2012

Keywords provided by New York State Psychiatric Institute:
intravenous abuse

Additional relevant MeSH terms:
Cocaine-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Buprenorphine
Cocaine
Analgesics, Opioid
Narcotics
Central Nervous System Depressants
Physiological Effects of Drugs
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Narcotic Antagonists
Anesthetics, Local
Anesthetics
Vasoconstrictor Agents
Dopamine Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Dopamine Agents
Neurotransmitter Agents